Download Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes Books PDF Free

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes PDF
By:
Published on 2016 by

Abstract : Aim: To explore the safety, pharmacokinetics and pharmacodynamics in humans of the unacylated ghrelin analogue AZP‐531, designed to improve glycaemic control and reduce weight. Methods: Assessments, including glucose measurements, were performed in a three‐part randomized study. In Part A, healthy subjects [n = 44, age 18–50 years, body mass index (BMI) 20–28 kg/m 2 ] received a single subcutaneous dose of 0.3, 3, 15, 30, 60 or 120 μg/kg AZP‐531 or placebo. In Part B, overweight/obese subjects (n = 32, age 18–65 years, BMI 28–38 kg/m 2 ) and in Part C, patients with type 2 diabetes [T2D; n = 36, age 18–65 years, BMI 20–40 kg/m 2, glycated haemoglobin (HbA1c) 7–10%] received AZP‐531 or placebo for 14 days (daily doses of 3, 15, 30 or 60 μg/kg and 15, 2 × 30 or 60 μg/kg, respectively). Results: AZP‐531 was well tolerated. Single‐ and multiple‐dose pharmokinetic variables were similar. Maximum AZP‐531 concentrations were typically reached at 1 h post‐dose. Observed maximum concentration (Cmax ) and area under the curve were dose‐proportional. The mean terminal half‐life (t1/2 ) was 2–3 h. In Part B, AZP‐531 doses of ≥15 μg/kg significantly improved glucose concentrations, without increasing insulin levels, suggesting an insulin‐sensitizing effect. AZP‐531 decreased mean body weight by 2.6 kg (vs 0.8 kg for placebo). In Part C, glucose variables improved in all groups, including placebo, suggesting a study effect in uncontrolled patients at baseline. Notwithstanding, AZP‐531 60 μg/kg reduced HbA1c by 0.4% (vs 0.2% for placebo) and body weight by 2.1 kg (vs 1.3 kg for placebo). Conclusions: AZP‐531 was well tolerated in this first‐in‐human study. Its pharmacokinetic profile, suitable for once‐daily dosing, and metabolic effects support further clinical development for T2D.

This Book was ranked at 22 by Google Books for keyword Pharmacodynamics.

Book ID of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes's Books is WsvQswEACAAJ, Book which was written by have ETAG "FxrCnfqKM90"

Book which was published by since 2016 have ISBNs, ISBN 13 Code is and ISBN 10 Code is

Reading Mode in Text Status is false and Reading Mode in Image Status is false

Book which have " Pages" is Printed at BOOK under Category

Book was written in en

eBook Version Availability Status at PDF is falseand in ePub is false

Book Preview

Download Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes PDF Free

Download Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes Books Free

Download Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes Free

Download Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes PDF

Download Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP‐531, a First‐in‐class Analogue of Unacylated Ghrelin, in Healthy and Overweight/obese Subjects and Subjects with Type 2 Diabetes Books